《结核病的变迁：当前趋势与未来需求》。
Curving Tuberculosis: Current Trends and Future Needs.
机构信息
Division of General Internal Medicine, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, US.
University Hospital of Gran Canaria "Dr. Negrin," Las Palmas, ES.
出版信息
Ann Glob Health. 2019 Jan 22;85(1):5. doi: 10.5334/aogh.2415.
Abstract
Tuberculosis (TB) presents new challenges as a global public health problem, especially at a time of increasing threats to some particular patients due to Human Immunodeficiency Virus (HIV) infection and multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of Mycobacterium tuberculosis. The World Health Assembly strives to reduce TB deaths by 95% and to decrease TB incidence by 95% by 2035. However, new approaches are necessary in order to attain these objectives. Such approaches include active ascertainment of cases in high risk populations, increasing the availability of accurate point-of-care testing, rapid detection of drug resistance, novel vaccines, and new prophylaxis and treatment regimens (particularly for MDR and XDR TB). The ultimate objective of those programs is to develop highly effective drug regimens that can achieve high cure rates regardless of strains' resistance patterns.
摘要
结核病（TB）作为一个全球公共卫生问题带来了新的挑战，尤其是在艾滋病毒（HIV）感染以及耐多药（MDR）和广泛耐药（XDR）结核分枝杆菌菌株对某些特定患者构成威胁的情况下。世界卫生大会力争到 2035 年将结核病死亡率降低 95%，发病率降低 95%。然而，为了实现这些目标，需要采取新的方法。这些方法包括在高危人群中积极确定病例，增加准确的即时检测的可获得性，快速检测耐药性，新型疫苗，以及新的预防和治疗方案（特别是针对耐多药和广泛耐药结核病）。这些计划的最终目标是开发出高效的药物方案，无论菌株的耐药模式如何，都能实现高治愈率。
相似文献
1
Curving Tuberculosis: Current Trends and Future Needs.《结核病的变迁：当前趋势与未来需求》。
Ann Glob Health. 2019 Jan 22;85(1):5. doi: 10.5334/aogh.2415.
2
HIV coinfection among multidrug resistant and extensively drug resistant tuberculosis patients--a trend.耐多药和广泛耐药结核病患者中的艾滋病毒合并感染——一种趋势。
J Indian Med Assoc. 2009 May;107(5):281-2, 284-6.
3
Household contact investigation of multidrug-resistant and extensively drug-resistant tuberculosis in a high HIV prevalence setting.高 HIV 流行环境中耐多药和广泛耐药结核病的家庭接触者调查。
Int J Tuberc Lung Dis. 2011 Sep;15(9):1170-5, i. doi: 10.5588/ijtld.10.0781.
4
Global trends, regional differences and age distribution for the incidence of HIV and tuberculosis co-infection from 1990 to 2019: results from the global burden of disease study 2019.全球趋势、区域差异和艾滋病毒与结核病合并感染发病率的年龄分布：2019 年全球疾病负担研究结果。
Infect Dis (Lond). 2022 Nov;54(11):773-783. doi: 10.1080/23744235.2022.2092647. Epub 2022 Jul 7.
5
Extensively drug-resistant tuberculosis in the United States, 1993-2007.1993 - 2007年美国广泛耐药结核病情况
JAMA. 2008 Nov 12;300(18):2153-60. doi: 10.1001/jama.300.18.2153.
6
Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines.结核病诊断、药物及疫苗进展综述
Clin Infect Dis. 2015 Oct 15;61Suppl 3(Suppl 3):S102-18. doi: 10.1093/cid/civ609.
7
Tuberculosis in a cohort of HIV-positive patients: epidemiology, clinical practice and treatment outcomes.一组HIV阳性患者中的结核病：流行病学、临床实践及治疗结果
Int J Tuberc Lung Dis. 2014 Jun;18(6):700-8. doi: 10.5588/ijtld.13.0778.
8
Tuberculosis in humans and its epidemiology, diagnosis and treatment in the United States.美国的人类结核病及其流行病学、诊断和治疗。
Int J Tuberc Lung Dis. 2010 Oct;14(10):1226-32.
10
The cursed duet today: Tuberculosis and HIV-coinfection.当今的致命组合：结核病与艾滋病毒合并感染。
Presse Med. 2017 Mar;46(2 Pt 2):e23-e39. doi: 10.1016/j.lpm.2017.01.017. Epub 2017 Feb 28.
引用本文的文献
1
Knowledge and Prevalence of Latent Tuberculosis Infection: A Feasibility and Pilot Study in a Primary Healthcare Setting in Rural Eastern Cape, South Africa.潜伏性结核感染的知晓率与患病率：南非东开普省农村地区基层医疗环境中的一项可行性及试点研究
Int J Environ Res Public Health. 2025 Feb 21;22(3):320. doi: 10.3390/ijerph22030320.
2
Structural Characterization of Encapsulin in Complex with Dye-Decolorizing Peroxide.与染料脱色过氧化物复合的封装菌素的结构表征
Microorganisms. 2024 Nov 30;12(12):2465. doi: 10.3390/microorganisms12122465.
3
Tuberculosis incidence in Brazil: time series analysis between 2001 and 2021 and projection until 2030.巴西的结核病发病率：2001 年至 2021 年的时间序列分析及 2030 年的预测。
Rev Bras Epidemiol. 2024 Jun 14;27:e240027. doi: 10.1590/1980-549720240027. eCollection 2024.
4
The structure of Mycobacterium thermoresistibile MmpS5 reveals a conserved disulfide bond across mycobacteria.耐热分枝杆菌 MmpS5 的结构揭示了分枝杆菌之间保守的二硫键。
Metallomics. 2024 Mar 12;16(3). doi: 10.1093/mtomcs/mfae011.
5
A novel chemokine biomarker to distinguish active tuberculosis from latent tuberculosis: a cohort study.一种新型趋化因子生物标志物，可区分活动性结核病与潜伏性结核病：一项队列研究。
QJM. 2023 Dec 27;116(12):1002-1009. doi: 10.1093/qjmed/hcad214.
6
Metformin Increases Cell Viability and Regulates Pro-Inflammatory Response to Mtb.二甲双胍可提高细胞活力并调节对结核分枝杆菌的促炎反应。
Infect Drug Resist. 2023 Jun 7;16:3629-3638. doi: 10.2147/IDR.S401403. eCollection 2023.
7
Recent Progress in the Development of Novel Mycobacterium Cell Wall Inhibitor to Combat Drug-Resistant Tuberculosis.新型分枝杆菌细胞壁抑制剂对抗耐药结核病研发的最新进展
Microbiol Insights. 2022 May 23;15:11786361221099878. doi: 10.1177/11786361221099878. eCollection 2022.
8
Organoids as a Powerful Model for Respiratory Diseases.类器官作为呼吸系统疾病的强大模型
Stem Cells Int. 2020 Mar 11;2020:5847876. doi: 10.1155/2020/5847876. eCollection 2020.
9
HAMLET, a protein complex from human milk has bactericidal activity and enhances the activity of antibiotics against pathogenic .哈姆雷特（HAMLET）是一种源自人乳的蛋白质复合物，具有杀菌活性，并能增强抗生素对病原体的作用。
Antimicrob Agents Chemother. 2019 Sep 9;63(12). doi: 10.1128/AAC.01193-19. Epub 2019 Oct 7.
10
Antibiotic resistance breakers: current approaches and future directions.抗生素耐药性破解者：当前方法和未来方向。
FEMS Microbiol Rev. 2019 Sep 1;43(5):490-516. doi: 10.1093/femsre/fuz014.
本文引用的文献
1
QFT-Plus: a plus in variability? - Evaluation of new generation IGRA in serial testing of students with a migration background in Germany.QFT-Plus：在变异性方面更胜一筹？——对德国具有移民背景学生进行系列检测时新一代IGRA的评估
J Occup Med Toxicol. 2017 Jan 5;12:1. doi: 10.1186/s12995-016-0148-z. eCollection 2017.
2
First independent evaluation of QuantiFERON-TB Plus performance.对结核感染T细胞检测Plus（QuantiFERON-TB Plus）性能的首次独立评估。
Eur Respir J. 2016 May;47(5):1587-90. doi: 10.1183/13993003.02033-2015. Epub 2016 Feb 11.
3
Bedaquiline and delamanid in tuberculosis.贝达喹啉与地拉米啶在结核病治疗中的应用
Expert Opin Pharmacother. 2015;16(15):2319-30. doi: 10.1517/14656566.2015.1080240. Epub 2015 Aug 19.
4
Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort.巴喹替尼治疗耐多药和广泛耐药结核病的同情使用：法国队列的中期分析。
Clin Infect Dis. 2015 Jan 15;60(2):188-94. doi: 10.1093/cid/ciu786. Epub 2014 Oct 15.
5
Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China.利奈唑胺治疗广泛耐药结核病的疗效、安全性和耐受性：中国的一项研究。
Eur Respir J. 2015 Jan;45(1):161-70. doi: 10.1183/09031936.00035114. Epub 2014 Sep 18.
6
High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses.尼日尔标准化短程耐多药结核病治疗治愈率高：无复发情况。
Int J Tuberc Lung Dis. 2014 Oct;18(10):1188-94. doi: 10.5588/ijtld.13.0075.
7
Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients.针对500多名连续患者的耐多药结核病的成功“孟加拉国9个月治疗方案” 。
Int J Tuberc Lung Dis. 2014 Oct;18(10):1180-7. doi: 10.5588/ijtld.14.0100.
8
Multidrug-resistant tuberculosis and culture conversion with bedaquiline.耐多药结核病与贝达喹啉的培养转换。
N Engl J Med. 2014 Aug 21;371(8):723-32. doi: 10.1056/NEJMoa1313865.
9
FDA approval of bedaquiline--the benefit-risk balance for drug-resistant tuberculosis.美国食品药品监督管理局批准贝达喹啉——耐多药结核病的获益-风险平衡
N Engl J Med. 2014 Aug 21;371(8):689-91. doi: 10.1056/NEJMp1314385.
10
ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use.欧洲呼吸学会/世界卫生组织结核病咨询委员会对一名儿童广泛耐药结核病管理的援助：使用德拉马尼的同情用药案例研究
Eur Respir J. 2014 Sep;44(3):811-5. doi: 10.1183/09031936.00060414. Epub 2014 May 15.
Zotero 插件